mycophenolate mofetil- mycophenolate mofetil tablet
american health packaging - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 500 mg - mycophenolate mofetil tablet, usp is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. mycophenolate mofetil tablets, usp should be used concomitantly with cyclosporine and corticosteroids. mycophenolate mofetil intravenous is an alternative dosage form to mycophenolate mofetil capsules, tablets and oral suspension. mycophenolate mofetil intravenous should be administered within 24 hours following transplantation. mycophenolate mofetil intravenous can be administered for up to 14 days; patients should be switched to oral mycophenolate mofetil as soon as they can tolerate oral medication. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. mycophenolate mofetil intravenous is contraindicated in patients who are allergic to polysorbate 80 (tween).
prezista tablet
janssen inc - darunavir (darunavir ethanolate) - tablet - 800mg - darunavir (darunavir ethanolate) 800mg - hiv protease inhibitors
aspirin and omeprazole delayed-release tab- aspirin and omeprazole tablet, film coated
innovida phamaceutique corporation - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - aspirin and omeprazole delayed-release tablets, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. the aspirin component of aspirin and omeprazole delayed-release tablets is indicated for: - reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, - reducing the combined risk of death and nonfatal mi in patients with a previous mi or unstable angina pectoris, - reducing the combined risk of mi and sudden death in patients with chronic stable angina pectoris, - use in patients who have undergone revascularization procedures (coronary artery bypass graft [cabg] or percutaneous transluminal coronary angioplasty [ptca]) when there is a pre-existing condition for which aspirin is already indicated. the omeprazole component of aspirin and
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 75mg - darunavir 75mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 150mg - darunavir 150mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 300mg - darunavir 300mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 400mg - darunavir 400mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 600mg - darunavir 600mg - hiv protease inhibitors
mylan-darunavir tablet
mylan pharmaceuticals ulc - darunavir - tablet - 800mg - darunavir 800mg - hiv protease inhibitors
auro-darunavir tablet
auro pharma inc - darunavir (darunavir propylene glycolate) - tablet - 400mg - darunavir (darunavir propylene glycolate) 400mg - hiv protease inhibitors